Effect of US Food and Drug Administration-Approved Pediatric Labeling on Dispensing of Extended-Release Oxycodone in the Outpatient Retail Setting

JAMA Pediatr. 2016 Nov 1;170(11):1103-1104. doi: 10.1001/jamapediatrics.2016.3197.

Authors

Jing Xu¹, Rajdeep Gill², Marisa Cruz¹, Judy Staffa², Peter Lurie¹

Affiliations

¹ Office of Public Health Strategy and Analysis, Office of Commissioner, US Food and Drug Administration, Silver Spring, Maryland.
² Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland.

PMID: 27612007
DOI: 10.1001/jamapediatrics.2016.3197

No abstract available

MeSH terms

Adolescent
Analgesics, Opioid / supply & distribution*
Child
Child, Preschool
Delayed-Action Preparations
Drug Labeling / legislation & jurisprudence*
Humans
Infant
Infant, Newborn
Legislation, Drug
Oxycodone / supply & distribution*
Pain / prevention & control
United States
United States Food and Drug Administration

Substances

Analgesics, Opioid
Delayed-Action Preparations
Oxycodone